ClinicalTrials.gg
Not yet recruitingNCT06198907JACKPOT33Updated Jan 10, 2024

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

A Phase 2 interventional study of Golidocitinib and Sintilimab in Non-Small-Cell Lung Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 21 under way, 4 of them phase 3. sintilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
20th of 45
69 · median 60
Started
2024
with 4 others
Phase 2
32 of 45
12 open now
Primary completion
2026-12
later than 14 of 20 live
Registered
35th of 45
by date

Among the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, this one is the 20th largest by planned enrollment, is one of 5 that started in 2024, is one of 32 in phase 2, reaches primary completion later than 14 of the 20 other live ones, and was the 35th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to provide a signed and dated, written .
  2. Adults aged ≥18 to 75 years.
  3. performance status 0-1.
  4. Predicted ≥ 12 weeks
  5. or cytologically confirmed non-small-cell lung cancer (NSCLC) , Stage IIIB/IIIC (not suitable for concomitant chemoradiotherapy) or Stage IV according to AJCC 8th
  6. Without EGFR or ALK mutations.
  7. Adequate bone marrow reserve and organ system functions.
  8. Patients with stable and symptomatic (BM) can be enrolled.

Part A Dose escalation:

Patients must have after or been refractory/intolerant to ≥ 1 prior systemic therapy(ies) for NSCLC

Part B dose expansion:

  1. At least one according to 1.1.
  2. Previously systemic untreated for advanced disease.
  3. TPS ≥ 50% (cohort 1), PD-L1 TPS 1-49% (cohort 2)

Exclusion criteria

Exclusion Criteria:

  1. Histopathology confirmed a mixture of NSCLC and small-cell lung cancer
  2. Known active central nervous system (CNS) and/or carcinomatous meningitis.
  3. Prior within 5 years
  4. History of organ transplantation or hematopoietic stem cell transplantation
  5. Sever lung function decline or interstitial lung disease that has required oral or IV
  6. Active disease requiring systemic therapy within 2 years
  7. Immunodeficiency, or being treated with therapy (including systemic glucocorticoid) within 7 days prior to the first dose of study treatment.
  8. Active infections
  9. Significant cardiac disorder
  10. Other serious or uncontrolled systemic diseases assessed by the investigator.

Part A Dose escalation:

  1. Prior systemic therapy with an , anti-PD-L1, anti-PD-L2, anti-CD137, or stimulatory or synergistic T-cell receptor (CTLA-4、OX-40、CD137) within 4 weeks

Part B Dose Expansion:

  1. Any prior systemic anti-tumor therapy
  2. Prior systemic immunotherapy, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or stimulatory or synergistic T-cell receptor (CTLA-4、OX-40、CD137)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Part A Dose escalation

    Dose escalation part Golidocitinib in combination with sintilimab

    Drug: Golidocitinib · Drug: Sintilimab

  • Experimental
    Part B Dose expansion cohort 1 (PD-L1 TPS ≥ 50%)

    Dose expansion cohort 1, Golidositinib plus Sintilimab following Sintilimab

    Drug: Golidocitinib · Drug: Sintilimab

  • Experimental
    Part B Dose expansion cohort 2 (PD-L1 TPS 1-49%)

    Dose expansion cohort 2, Golidositinib plus Sintilimab following Sintilimab + chemotherapy

    Drug: Golidocitinib · Drug: Sintilimab · Drug: platinum doublet chemotherapy

Interventions

  • Daily dosing of golidocitinib

  • Sintilimab, 200mg, intravenous, every 3 weeks.

  • Drugplatinum doublet chemotherapy

    Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) (cohort1)

    Complete response (CR) or partial response (PR) per investigator assessment according to RECIST 1.1

    Time frame: through study completion, an average of 1 year

  2. Progression-free survival (PFS) (cohort2)

    Time from first administration of study drug to first documented disease progression or death per investigator assessment according to RECIST 1.1

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Overall survival (OS)

    time from first administration of study drug to death

    Time frame: through study completion, up to 36 months

  2. Incidence of Adverse Events

    Frequency an severity of AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: through study completion, up to 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2026, 35 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 35 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2023
First posted
Jan 10, 2024
StartEst.
Jan 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06198907
Responsible party
Jie Wang (Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jan 10, 2024
Start date
Jan 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 10, 2024

Study contacts

Jie Wang, MD,PhD
Contact
zlhuxi@163.com
010-87788219
Jie Wang, MD,PhD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Golidocitinib · Sintilimab

Start the discussion